

# **Urology**

**Volume - 1**

**MARROW**  
— Super Speciality

## **Instructions**

- The notes must be used in conjunction with the Marrow SS Surgery videos and should not be considered standalone material.

## **Please note:**

- The information in this book has been printed based on the transcript of the Marrow SS Surgery videos.
- The information contained in this book is for educational purposes only. The content provided is not intended to substitute for professional medical advice, diagnosis or treatment.
- This book cannot be sold separately. It has been made available to only select eligible users who have an active subscription to Marrow SS Surgery videos.
- The text, images, slides, and other materials used in this book have been contributed by the faculty, who are subject matter experts. We have merely reproduced them as video transcripts in this book.
- The notes have been consciously designed in a way that is concise and revisable. To ensure this, we have intentionally added only the most relevant modules and images that are needed for you.
- Reasonable care has been taken to ensure the accuracy of the information provided in this book. Neither the faculty nor Marrow takes any responsibility for any liability or damages resulting from applying the information provided in this book.
- This set contains notes of all main videos published in the app until August 2025. You can find notes for any additional videos published after this date within the app under the videos section.

## **All Rights Reserved**

No part of this publication shall be reproduced, copied, transmitted, adapted, modified or stored in any form or by any means, electronic, photocopying, recording or otherwise.

© Marrow

// ME821-PPL

# Contents

## Volume - 1

### Introduction to Urology

- |    |                                      |    |
|----|--------------------------------------|----|
| 1. | Imaging in Urology                   | 1  |
| 2. | Ultrasonography and Nuclear Medicine | 12 |

### Basics of Urological Surgery

- |    |                        |    |
|----|------------------------|----|
| 3. | Instruments in Urology | 24 |
| 4. | Laparoscopy & Robotics | 52 |

### Reproductive Urology

- |    |                                 |     |
|----|---------------------------------|-----|
| 5. | Erectile Dysfunction            | 71  |
| 6. | Male Infertility                | 93  |
| 7. | Priapism and Peyronie's Disease | 114 |

### Prostate

- |     |   |     |
|-----|---|-----|
| 8.  | Prostate - Anatomy & Physiology             | 132 |
| 9.  | Benign Prostatic Enlargement - Epidemiology | 142 |
| 10. | BPE - Evaluation & Medical Management       | 146 |
| 11. | BPH - Surgical Management                   | 166 |
| 12. | Prostate Cancer : Part I                    | 179 |
| 13. | Prostate Cancer : Part II                   | 197 |
| 14. | Prostate Cancer : Part III                  | 218 |
| 15. | Radiation Therapy For Carcinoma Prostate    | 229 |
| 16. | Metastatic Prostate Cancer                  | 243 |

### Tumors of the Genitalia

- |     |                             |     |
|-----|-----------------------------|-----|
| 17. | Testicular Cancer : Part I  | 252 |
| 18. | Testicular Cancer : Part II | 266 |
| 19. | Tumors of Penis             | 278 |

## **Renal Urology**

- |                                  |     |
|----------------------------------|-----|
| 20. Renal Physiology and AKI-CKD | 295 |
|----------------------------------|-----|

## **Volume - 2**

### **Renal Tumors**

- |  |     |
|--|-----|
| 21. Renal Cell Carcinoma : Part I            | 325 |
| 22. Renal Cell Carcinoma : Part II           | 345 |
| 23. Renal Cell Carcinoma : Part III          | 359 |
| 24. Renal Transplantation                    | 374 |
| 25. Urothelial Tumors - Upper Tract & Ureter | 394 |

### **Bladder and Urethra**

- |  |     |
|--|-----|
| 26. Sphincteric Incontinence in Female                       | 407 |
| 27. Surgical Procedures For Sphincteric Incontinence in Male | 422 |
| 28. Pharmacology of LUTS                                     | 429 |
| 29. Pelvic Fracture Urethral injuries                        | 441 |
| 30. Urinary Bladder Cancer : Part I                          | 453 |
| 31. Urinary Bladder Cancer : Part II                         | 463 |
| 32. Urinary Diversions                                       | 475 |

### **Paediatric Urology**

- |  |     |
|--|-----|
| 33. Anterior Urethral Strictures                   | 487 |
| 34. Posterior Urethral Valve                       | 501 |
| 35. Renal Dysgenesis and Cystic Diseases of Kidney | 508 |
| 36. Ureteral Anomalies                             | 529 |

### **Infections**

- |                                       |     |
|---------------------------------------|-----|
| 37. Urinary Tract Infection : Part I  | 540 |
| 38. Urinary Tract Infection : Part II | 560 |

## **Urolithiasis**

- |     |   |     |
|-----|---|-----|
| 39. | Urolithiasis - Pathophysiology and Medical Management | 580 |
| 40. | Non Medical Management of Calculi                     | 608 |

## **Miscellaneous**

- |     |                                 |     |
|-----|---------------------------------|-----|
| 41. | Miscellaneous Topics in Urology | 622 |
|-----|---------------------------------|-----|



## IMAGING IN UROLOGY

----- Active space -----

### Radiation management

00:00:44

#### Terminologies :

- Radiation exposure :
  - Charge per unit mass of air caused by passage of radiation through tissue.
  - measured in coulombs (C)/kg.
- Absorbed dose :
  - Energy absorbed from radiation exposure.
  - measured in gray (Gy).
- Equivalent dose :
  - Conversion factor applied to absorbed dose to measure different interaction of radiation with different type of tissue.
  - measured in Sievert (Sv).
  - **Conversion factor** for diagnostic x rays = 1.
- Effective dose :
  - Denotes radiation risk to a population of patients from an imaging study.
  - measured in Sievert (Sv).
  - Estimation of range of effective doses for various imaging modalities allows assignment of relative.

Radiation quantity	Traditional unit	SI unit	Conversion	Clinical relevance
Exposure	roentgen (R)	coulomb / C/kg = 3876 R Charge per unit mass	1 C/kg = 3876 R	Charge per unit mass
Absorbed dose	rad	Gray (Gy)	1 Gy = 100 rad	Energy absorbed by tissue
Equivalent dose	rem	Sievert (Sv)	1 Sv = 100 rem	Absorbed energy based on tissue type
Effective dose	rem	Sievert (Sv)		Biologic risk associated with absorbed energy

----- Active space -----

- Radiation level :


Relative radiation level (RRL)	Effective dose estimated range	Example examinations
None	0	ultrasound, MRI
minimal	<0.1 mSv	Chest radiographs
Low	0.1-1.0 mSv	Lumbar spine radiographs, pelvic radiographs
medium	1-10 mSv	Abdomen CT without contrast, nuclear medicine, bone scan, mtc-DMSA renal scan, IVP, retrograde pyelograms, KUB, chest CT with contrast
High	10-100 mSv	Abdomen CT without and with contrast, whole-body PET

### Radiation protection :

- Recommended occupational exposure : 50 mSv/yr.
- No safe dose of radiation (Linear no threshold model).
- Greater risk to eyes and gonads.

### Reduction in radiation exposure :

- Limiting time of exposure :
  - use short bursts.
  - Last image hold.
- maximizing distance from radiation source :
  - Exposure diminishes as square of distance from radiation source.
  - Positioning image intensifier close to patient reduces scatter radiation.
- Shielding :
  - Radiation resistant eye protection, leaded gloves.
  - Collimate to minimum required visual fluoroscopy field.



Positioning of the radiation source

### Contrast media :

#### Allergy-like reactions :

- Idiosyncratic, anaphylactoid, not dose dependent.
- Differ immunologically from true allergic reactions.
- Antigen antibody response rarely identified, no true IgE reaction.
- mechanism of action : Combination of systemic effects :
  - Release of vasoactive substances like histamine.



----- Active space -----

- Activation of physiologic cascades : Complement, Kinin, coagulation, fibrinolytic systems.
- Inhibition of enzymes like cholinesterase leads to prolonged vagal stimulation.
- Patient anxiety and fear of actual procedure.

#### Physiologic reactions :

- Not allergy-like, dose and concentration dependent.
- Physiologic response to contrast medium molecular properties creating chemotoxicity.
- Effects can be due to hyperosmolality.
- Can also be due to binding of specific contrast molecules to activators.

<b>MILD REACTIONS</b>	
Self-limiting signs or symptoms	
<b>Allergic-Like</b>	<b>Physiologic</b>
Limited urticaria/pruritus	Limited nausea/emesis
Limited edema	Transient flushing/warm/chills
Limited throat irritation	Headache/dizziness/anxiety/altered taste
Nasal congestion	Mild hypertension
Sneezing, eye irritation, rhinorrhea	Vasovagal but resolves spontaneously
<b>MODERATE REACTIONS</b>	
Commonly require medical management and may become severe if not treated	
<b>Allergic-Like</b>	<b>Physiologic</b>
Diffuse urticaria/pruritus	Protracted nausea/emesis
Diffuse erythema	Hypertension
Facial edema	Chest pain
Throat tightness	Vasovagal responds to treatment
Wheezing/bronchospasm mild	
<b>SEVERE REACTIONS</b>	
Life-threatening, may result in morbidity or mortality if not treated. Cardiac arrest may occur from allergic-like as well as physiologic adverse reactions	
<b>Allergic-Like</b>	<b>Physiologic</b>
Diffuse edema/facial edema/shortness of breath	Vasovagal reaction resists treatment
Diffuse erythema and hypotension	Arrhythmia
Laryngeal edema with hypoxia	Seizures
Wheezing/bronchospasm with hypoxia	Hypertensive emergency
Anaphylactic shock/hypotension/tachycardia	

#### Treatment of contrast reactions :

##### mild :

- Observation, reassurance.
- Diphenhydramine, chlorpheniramine, diazepam.
- Bronchospasm management.

## ----- Active space -----

Moderate :

- Incidence : 0.5 to 2 %.
- Close observation.
- Hydrocortisone, salbutamol, oxygen.

Severe :

Emergency treatment :

- Rapid administration of **epinephrine (TOC)**.
- IV 0.1 ml/kg of 1:10000 dilution (0.01 mg/kg) slowly into running saline infusion, repeated every 5 to 15 min, maximum single dose 1 ml (0.1 mg), total dose 1 mg.
  - IM 0.01 mg/kg of 1:1000 dilution (0.01 ml/kg) to maximum 0.15 mg of 1:1000 if < 30 kg (0.3 mg if weight > 30 kg) in lateral thigh, repeated every 5 to 15 min up to 1 ml (1 mg).
- Vasopressors : most effective vasopressor : **Dopamine** (2 to 10 mcg/kg/min).

Premedication :

- No known strategy to eliminate risk of severe adverse reaction to contrast media.
- **Low osmolar contrast media** is preferred in patients with known history of allergy.
- AR may happen after extravascular procedures too (RGP).
- Corticosteroid premedication lowers likelihood of ALR.
- Adverse effect of premedication : Leukocytosis, asymptomatic hyperglycemia, possible infection risk.
- **Oral steroids** preferable.
- **Steroids required at least 6 hrs before** contrast media injection.
- Administration within 3 hrs not useful.
- Accelerated IV premedication only used when no alternatives present.
- Prednisone : 50 mg by mouth at 13 hours, 7 hours, and 1 hour before contrast media injection.
- Plus diphenhydramine (Benadryl) 50 mg intravenously, intramuscularly, or by mouth 1 hour before contrast medium injection.
- methylprednisolone (Medrol) : 32 mg by mouth 12 hours and 2 hours before contrast media injection.
- Plus diphenhydramine (Benadryl) : 50 mg intravenously, intramuscularly, or by mouth 1 hour before contrast medium injection.

### Delayed contrast reactions :

----- Active space -----

- Occur from 3 hrs to 7 days after contrast.
- m/c allergic like and cutaneous reactions.
- Typically resolve spontaneously.

### Specific contrast considerations :

- Allergic patients (unrelated to contrast) 2 to 3 times more likely to have contrast reaction.
- Reaction to 1 class doesn't increase risk of reaction to another type of contrast medium.
- Contrast reactions more common in patients with anxiety.
- Asthma increases chance of ALR (Premedication not recommended).
- Beta blockers can lower threshold for contrast reactions (Cessation not recommended).
- Premedication not recommended solely on cardiac status.
- Hyperthyroid patients may develop thyrotoxicosis with contrast (Rare).
- Washout of 3 to 6 wks recommended after contrast study before radioiodine therapy.
- Premedication not recommended for myasthenia gravis/pheochromocytoma/sickle cell trait.
- Large volume extravasation of contrast :
  - Swelling, edema, erythema, pain, cellulitis, compartment syndrome.
  - maximum symptoms in 24 to 48 hrs.
  - Primary mechanism : Hyperosmolality of contrast.
- Rx : manual massage, plastic surgery consult.

Post contrast AKI (Nonspecific term) : Acute, sudden deterioration in kidney function within 48 hrs.

### CIN :

- Specific for sudden decrease in kidney function by IV administration of iodinated contrast medium.
- Pathophysiology : vasoconstriction, direct tubular toxicity, osmotic mechanisms, chemotoxic mechanisms.
- Diagnosis of CIN → Occurrence within 48 hrs :
  - Increase in creatinine of  $> 0.3$  mg/dl.
  - Increase in creatinine from baseline  $> 50\%$ .
  - $\text{U/O} < 0.5$  ml/kg/hr for at least 6 hrs.

----- Active space -----

## • Risk factors :

- GFR at least 45 ml/min/1.73 m<sup>2</sup> not independent risk factor for CIN.
- IV contrast risk factor for CIN with GFR < 30 ml/min/1.73 m<sup>2</sup>.
- Incidence : 2 to 5 %.
- most important risk factor for CIN is **pre-existing severe renal insufficiency.**

## Other risk factors for CIN :

- DM.
- Dehydration.
- CV disease.
- Diuretic use.
- Advanced age.
- Multiple myeloma.
- HTN.
- Hyperuricemia.
- Repeated contrast injections.
- Low PCV.
- EF < 40%.
- Renal tumor/transplant/single kidney.
- HOCm, increased contrast viscosity.

## Prevention :

- Hydration.
- Sodium bicarbonate : Doubtful role.
- N acetyl cysteine : Controversial.

## metformin use :

- Advised discontinuation 48 hrs prior in patients with renal insufficiency.
- Fatal in 50 % cases.
- Rare with normal renal function.
- Discontinuation not required before Gd MRI.

## Note :

- Furosemide increases risk for CIN.
- ESRD with no natural renal function is no longer at risk for CIN.

**Gadolinium :**

- Paramagnetic metal ion.
- 7 unpaired electrons.
- Reduces T1 and T2 relaxation times.
- Increases tissue signal intensity on T1 weighted images.
- Can interfere with assay for Ca (False hypocalcemia for 24 hrs), iron, magnesium, iron binding capacity and zinc.

## Adverse effects :

----- Active space -----

## Nephrogenic systemic fibrosis :


- Fibrosing disease of skin, subcutaneous tissue, lungs, esophagus, heart and skeletal muscles.
- Initial features are skin thickening and pruritis.
- Later : Contractures and joint immobility, death due to visceral involvement.
- Strong association with advanced renal disease.
- Onset : 2 days to 3 months.
- Patients with  $GFR < 30$  not on chronic dialysis, most difficult patient population, IV contrast is contraindicated, Gd may cause NSF.
- NSF risk greatest with  $GFR < 15$  (1 to 7 % incidence).
- In high risk patients, use minimal dose, consider macrocyclic agents, avoid gadodiamide.
- **mechanism** : Gd dissociates from chelates in patients with poor renal clearance  $\rightarrow$  Free Gd binds phosphate and other anions  $\rightarrow$  Forms insoluble precipitate  $\rightarrow$  Deposited in tissues with subsequent fibrotic reaction.

## Plain imaging modalities

00:20:01

## IVU :


- Clear liquids 12 to 24 hr and enema 2 hr before procedure.
- Scout film : Non contrast image to see the location of stones.
- 50 to 100 ml contrast bolus.
- Nephrogenic phase immediately after injection.
- Next film at 5 minutes and every 5 minutes.
- Abdominal compression : visualization of ureters.
- Upright films possible for renal ptosis.
- Postvoid films taken.



IVU

## Plain abdominal radiography :

- Supine position.
- AP exposure.
- Level of diaphragm to inferior pubic ramus.
- Structures to look in plain abdominal radiograph :
  - Look for fractures of pelvis, hip and sacroiliac joint.
  - Renal shadow lying L1-L5.
  - Any foreign body and kidney stones can be visualised.
  - Psoas can be identified.
- Cost effective to monitor residual stone burden after treatment.



Plain abdominal radiography




----- Active space -----

**Retrograde pyelography :**

- Sterilize urine before study.
- Can determine ureteral normalcy distal to obstruction.
- Dilute contrast medium (50 % or less) to prevent subtle filling defects getting obscured.
- Evacuate air bubbles from syringe before instillation.
- 5 to 8 cc contrast usually required in normal syst.

**Complications :**

- Pyelotubular backflow : Opacification of medullary pyramids.
- Pyelosinus backflow : Tear in calyceal fornix leading to contrast leak in renal sinus.
- Pyelolymphatic backflow : Opacification of renal lymphatic channels.
- Pyelovenous backflow : Contrast entering venous system.



Pyelotubular backflow

Pyelosinus backflow

Pyelolymphatic backflow

**Loopography :**


- Advance catheter just proximal to abdominal wall fascia.
- Balloon inflated with 5 to 10 ml water.
- Oblique films useful.
- Drainage film useful.



Loopography

**Retrograde urethrography :**

- measures total length of urethral stricture.
- Anatomy of urethra distal to stricture visualised.



Retrograde urethrography

### Static cystography :

- Visualizes structural integrity of bladder.
- Shape and contour of bladder.
- Supine position.
- Bladder filled under gravity with 200 to 400 ml contrast.
- Oblique films useful (Diverticulae, fistulae).
- Post-drainage film required.
- As sensitive as CT cystography in detecting bladder rupture.



Static cystography

----- Active space -----

### Voiding cystography :

- Evaluates posterior urethra.
- VUR.
- Supine or semi upright position.
- B/l oblique views useful.

## CT

00:31:02

### Features :

- Attenuation of X ray photons passing through patient.
- Computer based reconstruction of cross sectional images.
- Amount of transmitted radiation measured by detector on opposite side of X ray beam.
- Helical (multidetector CT) : Patient moves through continuously rotating gantry.
- Current CT : 64 to 320 rows of detectors.
- Gray scale of each pixel of CT image depends on amount of radiation absorbed at that point → Attenuation value.
- Attenuation value is expressed in HU.
- Air HU = -1000, bone HU = +1000, water HU = 0.

### Phases of CECT :

- Unenhanced CT : 1<sup>st</sup> phase.
- Corticomedullary phase : 30 to 70 seconds, defines vasculature and perfusion.
- Nephrogenic phase : 90 to 180 seconds, allows sensitive detection and characterization of renal masses.
- Excretory phase : 3 to 5 minutes; visualization of PCS and ureter.

**Features :**

- Excellent signal contrast resolution of soft tissue.
- Free proton orient along magnetic Z axis.
- RF antenna or coil placed over area of interest.
- Coil transmits RF pulses through patient.
- Protons release energy on stopping RF pulse.
- T1 weighted images generated by time to return to equilibrium in Z axis, T2 weighted images in XY axis.
- T2 images : Water appears bright.
- Cortex brighter than medulla.




**Fat imaging :**

- Inversion recovery imaging.
- Chemical shift imaging (m.c.).
  - In phase and out of phase images taken.
  - Loss of signal on OP imaging s/o intracytoplasmic fat.
- Fat saturation imaging.
- Spectral presaturation with inversion recovery (SPIR).
- Spectral presaturation attenuated inversion recovery (SPAIR).

**Multiparametric MRI :**

- T2 weighted sequence.
- DWI : Texture of the organs.
- DCE :
  - Contrast enhancement.
  - Different curves are seen.
  - Type 1 curve → Straight upright curve.
  - Type 3 curve → malignancy.
- MRS : Depends on the level of choline, citrate and creatine.





Curves in DCE

----- Active space -----


# ULTRASONOGRAPHY AND NUCLEAR MEDICINE

## Ultrasonography

00:00:20

### Physical principles :

- USG waves produced by applying short bursts of alternating electrical current to series of crystals housed in transducer.
- Alternating expansion and contraction of crystals via **piezoelectric effect** creates mechanical wave.




- Longitudinal waves produced (Graphically sine wave).
- Reflected component of wave received by transducer.
- **Amplitude** : maximum excursion in positive or negative direction from baseline (Higher amplitude = brighter pixel).
- Wavelength : Distance between 2 peaks.
- Cycle : Complete path of wave between 2 peaks.
- 1 Hertz : 1 cycle/sec.
- Average **velocity of sound** in human tissues : **1540 m/s**.

### Resolution :

**Ability to discriminate** between 2 objects close to each other.

### Axial resolution :

- Ability to **identify as separate** 2 objects in direction of travelling wave.
- Dependent on frequency of sound waves.
- Higher frequency : Better axial resolution.



Resolution

### Lateral resolution :

----- Active space -----

- Ability to identify separately objects equidistant from transducer.
- Function of focused width of USG beam.
- Characteristic of transducer.
- Location of narrowest beam adjustable by user.
- more focused beam : Better lateral resolution at that location.
- Image quality enhanced by locating narrowest beam width (focus) at depth of object or tissue of interest.


High frequency transducers (7-18 MHz) : Less depth, better resolution (more absorption → Less reflection → Less depth).

Low frequency transducers (3-5 MHz) : more depth, less resolution.

### mechanisms of attenuation :

#### Reflection :

- Wave strikes an object, surface or boundary (interface) between unlike tissues.
- Affected by impedance of tissues.



#### Scattering :

- Sound waves strike small or irregular object.
- Produce spherical scatter waves.

#### Interference :

- Scatter waves collide in or out of phase.
- Pattern of interference responsible for echo architecture/texture of organs.
- 'Speckling' seen in organs with fine, internal histology (Testis).




#### Absorption :

- mechanical energy converted to heat.
- Absorption directly proportional to frequency.
- Higher frequency → Rapidly attenuated → Limited depth of penetration.
- As frequency goes up, depth of penetration decreases.

----- Active space -----

**Artifacts in ultrasound :****Acoustic shadowing :**

- Significant attenuation or reflection of sound waves at tissue interface.
- Echo information posterior to interface obscured.
- 3D objects appear crescentic, difficult to get accurate measurements.
- mitigated by changing angle of insonation, frequency of transducer or focal zone of transducer.



Acoustic shadowing




Increased through transmission

**Increased through transmission :**


- Less attenuation of waves while passing through an object.
- Waves passing through object (Simple cyst) has more energy.
- Reflected wave has more energy.
- Tissue posterior to cyst appears brighter.
- mitigated by changing angle of insonation or adjusting time gain compensation settings.

**Edging artifact :**

- Waves strike a curved surface or interface at incident angle : Refraction of wave along plane of interface.
- Overcome by changing angle of insonation.



mechanism of edging artifact



Edging artifact

**Reverberation artifact :**

- Large differences in impedance between 2 adjacent tissues.
- Strong reflection of incident wave.
- USG wave bounces back and forth b/w reflective interfaces.